Targeted Naltrexone to Support Individuals Participating in Dry January

Inclusion Criteria: * English speaking adults aged 18 and above * Intending to participate in "Dry January" in January of 2026 by either completely stopping or moderating (reducing) their drinking * Available to travel to BWH CCI outpatient facilities for study visits Exclusion Criteria: * DSM-5 diagnosis of moderate or severe AUD * Seeking treatment for AUD * Currently receiving medications for treating AUD (naltrexone, acamprosate, disulfiram) * CIWA score \> 3 at the time of enrollment * Blood alcohol level (BAL) \> 0 at enrollment * Current DSM-5 diagnosis of any other SUD except for tobacco use disorder * History of any inpatient alcohol withdrawal (i.e. "detox") admission * History of severe withdrawal syndrome including withdrawal seizure or delirium tremens * Active psychosis, mania, suicidality or homicidally or any psychiatric condition that impair ability to provide informed consent * Liver function test greater than 3 times upper normal limit or severe renal impairment * History of hypersensitivity or allergy to naltrexone * Currently or anticipating requiring opioid analgesics for pain during the trial * Pregnant or breastfeeding * Anticipated to permanently leave the Boston area during the duration of the trial. * Anticipated to be enrolled in another clinical drug trial during participation of this trial * Any other reason or clinical condition that the investigators judge may interfere with study participation and/or be unsafe for a participant